Injection Drug Use

4

Review clinical trials related to Injection Drug Use. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Feasibility of Internet-based HIV Prevention Research

The study will use social media to recruit a diverse sample of people who self-report injecting drugs, assessing the feasibility of online assessments and participants' ability to perform at-home self-administered HIV testing. Participants will complete online questionnaires at baseline and will be mailed HIV testing kits that they will self-administer and mail to a central laboratory. Investigators will track completion of questionnaires and whether at-home self-administered HIV tests were completed and sent to the laboratory.

Participants needed: 500
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Montefiore Medical CenterUpdated: Jun 4, 2026Locations: 1
Eligibility criteria

18 years or older [+4]

HIV status known to be positive

Status: Recruiting

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.

Participants needed: 100
Trial details
Phase: Phase 4Age: 18-64Biological sex: AllType: InterventionalSponsor: University of Alabama at BirminghamUpdated: Apr 22, 2026Locations: 1
Eligibility criteria

Provision of signed and dated informed consent. [+15]

Inability to give informed consent. [+29]

Status: Recruiting

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

The goal of this study is to determine the feasibility and impact of delivering long-acting injectable cabotegravir HIV pre-exposure prophylaxis and suite of support services to adults who inject non-prescription drugs who are risk for HIV through known sexual risk.

Participants needed: 100
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Massachusetts General HospitalUpdated: Mar 19, 2026Locations: 2
Eligibility criteria

HIV Ab/Ag test (lab-based or rapid) negative at time of enrollment [+5]

Pregnant or breastfeeding people. Should a participant become pregnant, the trea... [+4]

Status: Recruiting

Implementing Low-Barrier HCV Treatment in a Jail Setting

The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily. This study focuses on adults at the Rhode Island Department of Corrections who have active HCV and are awaiting trial. The study asks: * Can a simplified, low-barrier HCV treatment program work in a jail setting? * Do participants finish treatment and get cured using this approach? All participants will receive a 12-week course of the HCV medication sofosbuvir/velpatasvir (Epclusa). If they are released before completing treatment, they will take the remaining doses with them. Community Health Workers (CHWs) will help support participants after release, including reminding them to take medications and helping them get follow-up lab work. Researchers will measure: * Whether participants are cured of HCV * Whether the treatment approach is easy to use (feasible), acceptable, and followed correctly (fidelity) * Whether the program could be used in other jails or expanded in the future This study may help bring HCV treatment to more people in jail, reduce community spread of the virus, and support national goals to eliminate HCV.

Participants needed: 40
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: LifespanUpdated: Feb 27, 2026Locations: 1
Eligibility criteria

Incarcerated individual at RIDOC [+10]

Cirrhosis (FIB-4 Score >3.25 within 90 days prior to study entry and/or clinical... [+7]